Detalles de la búsqueda
1.
Obesity and heart failure with preserved ejection fraction.
Wiad Lek
; 77(3): 551-556, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38691799
2.
IS FECAL CALPROTECTIN DETERMINATION USEFUL FOR PATIENTS WITH METABOLIC ASSOCIATED FATTY LIVER DISEASE?
Pol Merkur Lekarski
; 51(4): 330-333, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37756451
3.
INFLUENCE OF COMPLEX TREATMENT ON BIOCHEMICAL BLOOD PARAMETERS OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND CONCOMITANT PRE-DIABETES.
Wiad Lek
; 74(4): 986-991, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34156017
4.
THE CLINICAL PRESENTATION OF SUBCLINICAL HYPOTHYROIDISM IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ASSOCIATED WITH OBESITY, ITS IMPACT ON CARDIOVASCULAR RISK, AND WAYS OF ITS CORRECTION.
Wiad Lek
; 74(10 cz 2): 2634-2639, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34923472
5.
Comparison of the effect of dapagliflozin on contrast to standard therapy of the patients with type 2 diabetes mellitus and concomitant obesity, their effect on laboratory and anthropometric parameters.
Wiad Lek
; 73(3): 457-461, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32285813
6.
Comorbidity severity index as a new tool for assessment of co-existing diseases in patients with non-alcoholic fatty liver disease at the carbohydrate metabolism disorder background and concomitant subclinical hypothyroidism.
Wiad Lek
; 72(4): 650-653, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31055550
Resultados
1 -
6
de 6
1
Próxima >
>>